Bildkälla: Stockfoto

AroCell Q2: Good cost control, somewhat lower sales - Redeye

Redeye returns with a more detailed take on the Q2 report and notes lower costs than expected and anticipate a continuous upswing of TUBEX sales while lowering FY 2022E sales somewhat. We reiterate our fair value range.

Redeye returns with a more detailed take on the Q2 report and notes lower costs than expected and anticipate a continuous upswing of TUBEX sales while lowering FY 2022E sales somewhat. We reiterate our fair value range.
Börsvärldens nyhetsbrev
ANNONSER